Hereditary nonpolyposis colorectal cancer secondary prevention
|
Hereditary Nonpolyposis Colorectal Cancer Microchapters |
|
Differentiating Hereditary Nonpolyposis Colorectal Cancer from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hereditary nonpolyposis colorectal cancer secondary prevention On the Web |
|
American Roentgen Ray Society Images of Hereditary nonpolyposis colorectal cancer secondary prevention |
|
FDA on Hereditary nonpolyposis colorectal cancer secondary prevention |
|
CDC on Hereditary nonpolyposis colorectal cancer secondary prevention |
|
Hereditary nonpolyposis colorectal cancer secondary prevention in the news |
|
Blogs on Hereditary nonpolyposis colorectal cancer secondary prevention |
|
Directions to Hospitals Treating Hereditary nonpolyposis colorectal cancer |
|
Risk calculators and risk factors for Hereditary nonpolyposis colorectal cancer secondary prevention |
Overview
Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include genetic testing, colonoscopy, urine cytology, pelvic exam and endometrial biopsy.
Secondary prevention
Recent studies demonstrate a reduced incidence in Lynch Syndrome patients who were exposed to at least four years of high-dose aspirin, with a satisfactory risk profile.[28] These results have been widely covered in the media; future studies will look at modifying (lowering) the dose (to reduce risk associated with the high dosage of ASA).
Secondary prevention strategies following hereditary nonpolyposis colorectal cancer include:
- Colonoscopy 25-35 years (2 years)
- Pelvic exam, transvaginal ultrasound and CA-125 25-35 years (Every year)
- Endometrial biopsy
- Urine cytology - Families who have someone diagnosed with transitional cell carcinoma of the ureter or renal pelvis 25-35 years - Every year